![immunology_respiratory immunology_respiratory](/sites/default/files/2023-02/immunology_respiratory.jpg)
About our Respiratory Diseases efforts
We are building on a heritage of more than a century in respiratory diseases, with treatments in asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and progressive fibrotic interstitial lung diseases. Our R&D approach leverages our deep understanding and extensive expertise in respiratory medicine, inflammation and fibrosis to develop the next generation of innovative therapies for patients with a broad range of lung diseases who have a high unmet medical need.
Selection of projects in February 2024
Phase 1 studies are usually designed with an emphasis on the assessment of safety and tolerability of an investigational drug in a small group of people for the first time. It can include healthy participants or participants with the disease.
![Ion channel inhibitor.png](/sites/default/files/2023-11/Ion%20channel%20inhibitor.png)
Ion channel inhibitor
![Lysophospholipase inhibitor](/sites/default/files/2023-12/Ion%20channel%20inhibitor.png)
Lysophospholipase inhibitor
![Anti-fibrotic agent](/sites/default/files/2024-04/Anti-fibrotic%20agent.png)
IL11 antibody
Phase 2 studies are usually designed to begin to evaluate the efficacy of an investigational drug in a higher number of participants with the disease, and often used to obtain dose-ranging information. Safety also continues to be assessed during this phase.
![BI 1291583.png](/sites/default/files/2023-11/BI%201291583.png)
BI 1291583
Phase 3 studies are designed to confirm the data of Phase 2 studies for an investigational drug. Large numbers of participants with the disease are generally involved to obtain safety and efficacy data to evaluate the overall benefit-risk relationship of an investigational drug to provide an adequate basis for regulatory approvals. Given the size of these studies and to ensure a representative sample of patients, they are often conducted across several countries.
![BI 1015550.png](/sites/default/files/2023-11/BI%201015550.png)
Nerandomilast (BI 1015550)
![BI 1015550-1.png](/sites/default/files/2023-11/BI%201015550-1.png)
Nerandomilast (BI 1015550)
Indication abbreviations
IPF: Idiopathic pulmonary fibrosis
nCFB: non-cystic fibrosis bronchiectasis
PPF: Progressive pulmonary fibrosis